Sudden cardiac death is one of the leading causes of death in the western industrial nations. Most people are affected by coronary heart disease (coronary heart disease, CHD) or heart muscle (cardiomyopathy). These can lead to life-threatening cardiac arrhythmias. If the heartbeat is too slow due to impulse or conduction disturbances, cardiac pacemakers will be implanted. High-frequency and lifethreatening arrhythmias of the ventricles (ventricular tachycardia, flutter or fibrillation) cannot be treated with a pacemaker. In such cases, an implantable cardioverterdefibrillator (ICD) is used, which additionally also provides all functions of a pacemaker. The implantation of a defibrillator is appropriate if a high risk of malignant arrhythmias has been established (primary prevention). If these life-threatening cardiac arrhythmias have occurred before and are not caused by a treatable (reversible) cause, ICD implantation will be used for secondary prevention. The device can stop these lifethreatening cardiac arrhythmias by delivering a shock or rapid impulse delivery (antitachycardic pacing) to prevent sudden cardiac death. Another area of application for ICD therapy is advanced heart failure (heart failure), in which both main chambers and / or different wall sections of the left ventricle no longer work synchronously. This form of cardiac insufficiency can be treated by electrical stimulation (cardiac resynchronization therapy, CRT). Since the affected patients are also at increased risk for sudden cardiac death, combination devices are usually implanted, which combine heart failure treatment by resynchronization therapy and the prevention of sudden cardiac death by life-threatening arrhythmia of the heart chambers (CRT-D device). An ICD is implanted subcutaneously or under the pectoral muscle in the area of the left collarbone. Like pacemaker implantation, ICD implantation is a routine, low-complication procedure today.
Introduction
An implantable cardioverterdefibrillator (ICD) has been used as an effective mortality-reducing therapy for the prevention of sudden cardiac death for over 30 years. When choosing an ICD therapy, however, it must also be taken into account that complications (e.g.
infections, thromboses, malfunctions) and inadequate shocks that are stressful for the patient may occur, so that careful evaluation of indication is essential.
For the use ICD for protection against sudden cardiac death, two different forms of prevention are generally distinguished: 1. Secondary Prevention, if an ICD is used after a so-called index event, which usually is a tachycardia-related cardiac arrest (or weaker symptoms such as (pre-) syncope or low blood pressure With persistent (more than 30 seconds) ventricular tachycardias that are hemodynamically tolerated (i.e., "stable"), the study situation is much less clear. If necessary, the data from the AVID register can be used to prove the secondary prophylactic benefit of an ICD in this constellation. 3 However, there is an expert opinion-based indication to consider the implantation of a defibrillator with stable ventricular tachycardia (evidence level C, class IIa according to ESC guidelines).
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Primary prevention in patients with ventricular dysfunction
Since most patients do not survive out-of-hospital cardiovascular arrest, the goal of primary prevention is to identify high-risk patients and implant defibrillators. According to current guidelines, patients with ventricular dysfunction LVEF < 35%, an ICD Implantation is recommended. 7-9 The DANISH study published in 2016 following the publication of the ESC guidelines does not find a clear survival advantage of ICD therapy in patients with systolic heart failure caused by coronary heart disease.
10
In the absence of randomized controlled trials, the authors of the current ESC guidelines do not recommend ICD implantation for primary prevention in NYHA Class I patients and in patients with a LVEF> 35%.
1 Generally, ICD implantation as primary prevention in patients with ventricular dysfunction is indicated only if optimized drug therapy has been performed for at least three months, the life expectancy in good functional status is more than one year and the ICD implantation is not < 40 days after a myocardial infarction.
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Cardiomyopathies
The indication for dilated cardiomyopathy (DCM) depends essentially on the conditions for secondary prevention or primary prevention in patients with ventricular dysfunction (see above).The secondary prophylactic indication for hypertrophic cardiomyopathy (HCM) obeys the principles already outlined above. Although there are no prospective randomized studies on ICD therapy in HCM, cohort studies and meta-analyzes show that fatal cardiac arrhythmias are often followed by surviving sudden cardiac arrest or persistent ventricular tachycardia. 
